Safety and efficacy of an alternative basiliximab (Simulect) regiment after renal transplantation: administration of a single 40-mg dose on the first postoperative day in patients receiving triple therapy with azathioprine
- 1 January 2003
- journal article
- Published by Frontiers Media SA in Transplant International
- Vol. 16 (1) , 45-52
- https://doi.org/10.1111/j.1432-2277.2003.tb00222.x
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- A RANDOMIZED, DOUBLE-BLIND TRIAL OF BASILIXIMAB IMMUNOPROPHYLAXIS PLUS TRIPLE THERAPY IN KIDNEY TRANSPLANT RECIPIENTS1,2Transplantation, 2001
- Rapid steroid withdrawal versus standard steroid therapy in patients treated with basiliximab, cyclosporine, and mycophenolate mofetil for the prevention of acute rejection in renal transplantationTransplantation Proceedings, 2001
- Induction strategy using basiliximab combined with mycophenolate MMF and immediate low-dose cyclosporin is steroid sparing and more effective than OKT3Transplantation Proceedings, 2001
- The Banff 97 working classification of renal allograft pathologyKidney International, 1999
- REDUCTION OF THE OCCURRENCE OF ACUTE CELLULAR REJECTION AMONG RENAL ALLOGRAFT RECIPIENTS TREATED WITH BASILIXIMAB, A CHIMERIC ANTI-INTERLEUKIN-2-RECEPTOR MONOCLONAL ANTIBODY1,2Transplantation, 1999
- DISPOSITION OF BASILIXIMAB, AN INTERLEUKIN-2 RECEPTOR MONOCLONAL ANTIBODY, IN RECIPIENTS OF MISMATCHED CADAVER RENAL ALLOGRAFTS1Transplantation, 1997
- Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipientsThe Lancet, 1997
- PROLONGED ACTION OF A CHIMERIC INTERLEUKIN-2 RECEPTOR (CD25) MONOCLONAL ANTIBODY USED IN CADAVERIC RENAL TRANSPLANTATIONTransplantation, 1995